Lincoln Pharmaceuticals Limited
BSE: LINCOPH
BSE
638.15
-12.05 (-1.85%)
Prev Close
650.2
Open Price
664.95
Volume
2,082
Today Low / High
635 / 664.95
52 WK Low / High
85.5 / 664.95
Range
606 - 670
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 638.15, reflecting a change of -12.05 (-1.8533%). The expected target range on the BSE is 606 - 670. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.
Lincoln Pharmaceuticals Limited Graph
Lincoln Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lincoln Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 638.15, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 638.15 | 644.53 | 580.08 - 708.98 |
| 650.91 | 520.73 - 781.10 | ||
| 657.29 | 460.11 - 854.48 | ||
| Bearish Scenario | 638.15 | 631.77 | 568.59 - 694.95 |
| 625.39 | 500.31 - 750.46 | ||
| 619.01 | 433.30 - 804.71 |
Overview of Lincoln Pharmaceuticals Limited
ISIN
INE405C01035
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
15,668
Market Cap
12,763,000,638
Last Dividend
1.5
Official Website
IPO Date
2002-07-01
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of LINCOPH
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2023-09-15 | September 15, 23 | 1.5 | 1.5 | 2023-09-15 | 2023-10-30 | |
| 2022-09-15 | September 15, 22 | 1.5 | 1.5 | 2022-09-16 | 2022-10-30 | |
| 2021-09-16 | September 16, 21 | 1.5 | 1.5 | 2021-09-17 | 2021-10-30 | |
| 2020-03-05 | March 05, 20 | 1.5 | 1.5 | 2020-03-06 | 2020-03-28 | |
| 2019-09-19 | September 19, 19 | 1.5 | 1.5 | 2019-09-20 | 2019-10-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 505.82 Cr | 374.72 Cr | 131.10 Cr | 0.2592 | 11.77 Cr | 0.00 Cr | 77.99 Cr | 72.90 Cr | 36.40 | 87.16 Cr | 0.1441 |
| 2022-03-31 | 468.81 Cr | 323.68 Cr | 145.13 Cr | 0.3096 | 0.00 Cr | 0.00 Cr | 86.03 Cr | 69.36 Cr | 34.63 | 94.12 Cr | 0.1479 |
| 2021-03-31 | 415.21 Cr | 295.32 Cr | 119.89 Cr | 0.2887 | 9.36 Cr | 0.00 Cr | 72.02 Cr | 62.25 Cr | 31.08 | 79.58 Cr | 0.1499 |
| 2020-03-31 | 377.39 Cr | 274.52 Cr | 102.87 Cr | 0.2726 | 8.30 Cr | 0.00 Cr | 50.78 Cr | 51.44 Cr | 25.72 | 58.10 Cr | 0.1363 |
| 2019-03-31 | 357.47 Cr | 262.15 Cr | 95.32 Cr | 0.2666 | 8.94 Cr | 0.00 Cr | 52.93 Cr | 48.71 Cr | 24.36 | 59.63 Cr | 0.1363 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 5.22 Cr | 588.13 Cr | 85.65 Cr | 502.4744 Cr | 2.00 Cr | -3.22 Cr | 70.03 Cr | 158.49 Cr | 0.82 Cr | 0.00 Cr | 60.61 Cr | 72.2841 Cr |
| 2022-03-31 | 7.42 Cr | 534.83 Cr | 101.95 Cr | 432.8774 Cr | 2.04 Cr | -5.37 Cr | 72.74 Cr | 150.63 Cr | 0.12 Cr | 0.00 Cr | 29.41 Cr | 90.4862 Cr |
| 2021-03-31 | 13.84 Cr | 453.12 Cr | 86.73 Cr | 366.3923 Cr | 0.52 Cr | -13.32 Cr | 46.61 Cr | 114.49 Cr | 3.54 Cr | 0.00 Cr | 26.32 Cr | 75.8403 Cr |
| 2020-03-31 | 14.58 Cr | 390.38 Cr | 76.91 Cr | 313.0889 Cr | 5.07 Cr | -9.51 Cr | 47.40 Cr | 113.30 Cr | 1.53 Cr | 0.00 Cr | 15.32 Cr | 65.5826 Cr |
| 2019-03-31 | 7.58 Cr | 366.92 Cr | 97.22 Cr | 269.3446 Cr | 33.61 Cr | 26.03 Cr | 36.23 Cr | 113.37 Cr | 0.25 Cr | 0.00 Cr | 16.12 Cr | 85.3362 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 38.8350 Cr | -37.5681 Cr | -3.1489 Cr | 24.5530 Cr | -1.8820 Cr | -1.8820 Cr | -14.2820 Cr | 72.8993 Cr | 0.0000 Cr | -3.0045 Cr | 2.7141 Cr |
| 2022-03-31 | 77.7250 Cr | -80.7096 Cr | -1.5197 Cr | 32.1999 Cr | -4.5043 Cr | -4.5043 Cr | -45.5251 Cr | 69.3551 Cr | 0.0000 Cr | -3.0000 Cr | -26.1292 Cr |
| 2021-03-31 | 70.1376 Cr | -66.2864 Cr | -4.5543 Cr | 61.3873 Cr | -0.7031 Cr | -0.7031 Cr | -8.7503 Cr | 62.2501 Cr | 0.0000 Cr | 0.0000 Cr | 0.7832 Cr |
| 2020-03-31 | 74.9327 Cr | -32.3910 Cr | -35.7680 Cr | 67.2419 Cr | 6.7737 Cr | 6.7737 Cr | -7.6908 Cr | 51.4392 Cr | 0.0000 Cr | -7.2334 Cr | -11.1703 Cr |
| 2019-03-31 | 48.9864 Cr | -18.8032 Cr | -31.2943 Cr | 34.0486 Cr | -1.1111 Cr | -1.1111 Cr | -14.9378 Cr | 48.7101 Cr | 0.0000 Cr | -3.6167 Cr | 9.1857 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | 146.45 Cr | 96.34 Cr | 50.11 Cr | 0.3422 | 26.85 Cr | 28.04 Cr | 14.00 | 29.66 Cr | 0.1915 |
| 2023-09-30 | 155.99 Cr | 101.35 Cr | 54.64 Cr | 0.3503 | 28.57 Cr | 27.65 Cr | 13.81 | 31.15 Cr | 0.1773 |
| 2023-06-30 | 135.62 Cr | 92.86 Cr | 42.76 Cr | 0.3153 | 18.17 Cr | 19.01 Cr | 9.49 | 20.72 Cr | 0.1402 |
| 2023-03-31 | 112.46 Cr | 73.97 Cr | 38.49 Cr | 0.3423 | 14.23 Cr | 12.56 Cr | 6.27 | 16.64 Cr | 0.1117 |
| 2022-12-31 | 133.77 Cr | 89.62 Cr | 44.14 Cr | 0.3300 | 24.49 Cr | 21.61 Cr | 10.79 | 26.75 Cr | 0.1616 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | 38.46 Cr | 132.32 Cr | 170.78 Cr | 187.51 Cr | 65.59 Cr | 438.96 Cr | 156.10 Cr | 663.27 Cr | 117.28 Cr |
| 2023-03-31 | 5.22 Cr | 120.42 Cr | 125.65 Cr | 162.48 Cr | 70.03 Cr | 367.21 Cr | 158.49 Cr | 588.13 Cr | 85.65 Cr |
| 2022-09-30 | 21.25 Cr | 101.20 Cr | 122.45 Cr | 199.51 Cr | 78.76 Cr | 414.30 Cr | 153.29 Cr | 603.43 Cr | 134.77 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2009-03-19 | March 19, 09 | 1:5 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,641.80 | ₹3,939,137,904,000.00 | ₹2,098,280.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,151.50 | ₹1,633,032,553,500.00 | ₹681,521.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,685.30 | ₹1,247,271,358,500.00 | ₹279,863.00 |
| Mankind Pharma Limited | MANKIND | ₹2,606.80 | ₹1,075,901,331,568.00 | ₹731,305.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,277.60 | ₹1,063,387,459,020.00 | ₹1,229,762.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.80 | ₹994,960,224,000.00 | ₹307,413.00 |
| Lupin Limited | LUPIN | ₹1,974.70 | ₹901,938,300,900.00 | ₹380,522.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,426.00 | ₹648,759,690,000.00 | ₹99,581.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.40 | ₹610,074,420,800.00 | ₹1,872,840.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,937.30 | ₹546,707,997,300.00 | ₹466,930.00 |
| Laurus Labs Limited | LAURUSLABS | ₹879.10 | ₹474,560,157,500.00 | ₹1,548,001.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,418.40 | ₹359,853,753,600.00 | ₹437,395.00 |
| Cohance Lifesciences Limited | COHANCE | ₹884.70 | ₹338,457,031,978.00 | ₹105,334.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,638.50 | ₹329,643,636,000.00 | ₹49,045.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,747.90 | ₹273,268,433,900.00 | ₹250,994.00 |
| Piramal Enterprises Limited | PEL | ₹1,167.70 | ₹264,691,900,600.00 | ₹183,898.00 |
| Eris Lifesciences Limited | ERIS | ₹1,768.70 | ₹240,909,320,900.00 | ₹37,828.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,479.40 | ₹240,371,432,600.00 | ₹246,819.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,433.00 | ₹210,825,000,000.00 | ₹11,150.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹974.60 | ₹191,570,299,800.00 | ₹29,498.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,888.00 | ₹178,181,651,200.00 | ₹28,474.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,083.00 | ₹172,501,323,000.00 | ₹140,398.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,168.10 | ₹164,800,966,770.00 | ₹172,510.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹882.45 | ₹158,055,619,500.00 | ₹259,072.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹458.50 | ₹111,252,274,000.00 | ₹945,550.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,581.50 | ₹109,248,951,100.00 | ₹46,177.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹851.90 | ₹83,308,067,710.00 | ₹36,218.00 |
| Strides Pharma Science Limited | STAR | ₹865.50 | ₹79,775,471,850.00 | ₹92,326.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹863.25 | ₹78,240,335,715.00 | ₹294,141.00 |
| FDC Limited | FDC | ₹474.65 | ₹77,277,766,500.00 | ₹198,253.00 |
| Innova Captab Limited | INNOVACAP | ₹911.35 | ₹52,151,939,956.00 | ₹70,484.00 |
| Suven Life Sciences Limited | SUVEN | ₹230.75 | ₹50,320,575,500.00 | ₹56,095.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹146.08 | ₹47,406,173,760.00 | ₹195,028.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹483.05 | ₹44,087,973,500.00 | ₹160,106.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.85 | ₹44,021,409,750.00 | ₹240,104.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.20 | ₹39,165,289,020.00 | ₹31,316.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,358.20 | ₹39,002,269,800.00 | ₹5,512.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹363.25 | ₹36,425,983,500.00 | ₹39,528.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹502.80 | ₹35,400,036,240.00 | ₹9,585.00 |
| Hikal Limited | HIKAL | ₹254.90 | ₹31,429,424,900.00 | ₹3,140,867.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹631.60 | ₹30,413,434,800.00 | ₹53,855.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.82 | ₹28,419,284,140.00 | ₹848,541.00 |
| Alembic Limited | ALEMBICLTD | ₹105.52 | ₹27,095,636,534.00 | ₹249,022.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.03 | ₹26,866,184,620.00 | ₹2,369,065.00 |
| Indoco Remedies Limited | INDOCO | ₹279.55 | ₹25,787,900,445.00 | ₹12,570.00 |
Key Executives
No executive data available.
FAQs about Lincoln Pharmaceuticals Limited
What is the current market price of the stock?
The current price is ₹638.15.
What is the 52-week price range?
The range is ₹85.5-664.95.
What is the market capitalization of the company?
The market capitalization is ₹1,276.30 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 17.53.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Lincoln Pharmaceuticals Limited (ISIN: INE405C01035) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,276.30 crores and an average daily volume of 15,668 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.5.